Discussion
The U.S. Food and Drug Administration (FDA) has expanded its approval of Vonvendi (recombinant von Willebrand factor), a treatment for von Willebrand disease (VWD).
Von Willebrand disease
Von Willebrand disease is a genetic bleeding disorder that impairs the body’s ability to form proper blood clots. It can cause frequent or prolonged bleeding episodes, but many people experience only mild or manageable symptoms.
Treatment for von Willebrand disease focuses on preventing and controlling bleeding to improve daily life and reduce serious risks. Management plans vary by disease type and may involve ongoing monitoring and personalized care strategies.
Latest news
Discussion
Discussion
The severity of bleeding in type 2 von Willebrand disease (VWD) can vary widely between subtypes and even among patients who carry the same…